Related Experiment Video
Updated: Jul 17, 2025
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
A Targeted Exosome Therapeutic Confers Both CfDNA Scavenging and Macrophage Polarization for Ameliorating Rheumatoid
Zhe Wang1,2,3, Chuanjie Zhang1,3, Jiaqi Meng2
1Department of Orthopedics, Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, 121002, P. R. China.
Abstract:
Only a minority of rheumatoid arthritis (RA) patients achieve disease remission, so the exploration of additional pathogenic factors and the development of new therapeutics are needed. Here, strong correlations among the cell-free DNA (cfDNA) level and the inflammatory response in clinical synovial fluid samples and RA disease activity are discovered. The important role of cfDNA in disease development in a collagen-induced arthritis (CIA) murine model is also demonstrated. Building on these findings, a novel therapeutic based on anti-inflammatory (M2) macrophage-derived exosomes as chassis, that are modified with both oligolysine and matrix metalloproteinase (MMP)-cleavable polyethylene glycol (PEG) on the membrane, is developed. After intravenous injection, PEG-enabled prolonged circulation and C─C motif chemokine ligand-directed accumulation together result in enrichment at inflamed joints. Following subsequent MMP cleavage, the positively charged oligolysine is exposed for cfDNA scavenging, while exosomes induce M2 polarization. By using a classical CIA murine model and a newly established CIA canine model, it is demonstrated that the rationally designed exosome therapeutic substantially suppresses inflammation in joints and provides strong chondroprotection and osteoprotection, revealing its potential for effective CIA amelioration.
Insights
Researchers discovered cell-free DNA (cfDNA) correlates with rheumatoid arthritis (RA) activity. A novel exosome therapy targeting cfDNA and inflammation in joints shows promise for treating arthritis in mouse and canine models.
Area of Science:
- Immunology
- Biomedical Engineering
- Rheumatology
Background:
- Rheumatoid arthritis (RA) affects many, with few achieving remission, necessitating new therapeutic strategies.
- Cell-free DNA (cfDNA) is implicated in RA pathogenesis, correlating with inflammation and disease activity.
- Existing RA treatments have limitations, driving the search for novel therapeutic targets and delivery systems.
Purpose of the Study:
- To investigate the role of cfDNA in rheumatoid arthritis pathogenesis.
- To develop and evaluate a novel exosome-based therapeutic for RA.
- To assess the efficacy of the engineered exosome therapy in preclinical arthritis models.
Main Methods:
- Correlating cfDNA levels with synovial fluid inflammation and RA disease activity in patients.
- Utilizing a collagen-induced arthritis (CIA) murine model to study cfDNA's role.
- Engineering exosomes derived from M2 macrophages with oligolysine and MMP-cleavable PEG.
- Evaluating the therapeutic's biodistribution, cfDNA scavenging, and anti-inflammatory effects in CIA murine and canine models.
Main Results:
- Strong correlations found between cfDNA levels, synovial inflammation, and RA disease activity.
- cfDNA demonstrated a significant role in CIA pathogenesis in a murine model.
- The engineered exosome therapy exhibited prolonged circulation and targeted accumulation at inflamed joints.
- The therapy effectively reduced joint inflammation, protected cartilage, and prevented bone erosion in both murine and canine CIA models.
Conclusions:
- cfDNA is a significant factor in RA and CIA pathogenesis.
- Engineered M2 macrophage-derived exosomes represent a promising therapeutic platform for RA.
- The novel exosome therapy demonstrates substantial anti-inflammatory, chondroprotective, and osteoprotective effects in preclinical models.
- This therapeutic strategy holds potential for ameliorating collagen-induced arthritis and related inflammatory joint diseases.
More Related Videos
09:18Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue
Published on: February 24, 2023
09:20Differentiation of Monocytes into Phenotypically Distinct Macrophages After Treatment with Human Cord Blood Stem Cell CB-SC-Derived Exosomes
Published on: November 12, 2020